โ ExplanationAdvancedIndustry Deep Dives โบ Healthcare & Pharma
Seaport Therapeutics Jumps 12%: What the Biotech Move Signals
Seaport Therapeutics shares rose roughly 12% in the latest session, drawing attention to its clinical pipeline and the unusually binary risk profile of early-stage biotechnology stocks.
4mยท๐ 0
โ ExplanationBuildingInvesting & Markets โบ Stock Market & Equities
The Gamma Trap: How Options Volatility is Decoupling Biotech Fundamentals
A surge in high-frequency options trading within the mid-cap biotech sector is creating a 'gamma squeeze' that artificially inflates stock prices regardless of clinical trial outcomes. This technical anomaly poses a significant risk for retail investors who mistake price momentum for medical breakthroughs.
5mยท๐ 0